Our CEO, Cory R. Nicholas, PhD, was recently featured in a blog by the California Institute for Regenerative Medicine, in which he provided an update on the clinical development of NRTX-1001, our off-the-shelf neural cell therapy designed to treat drug-resistant focal epilepsy. The discussion highlighted the recent U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for NRTX-1001, as well as the novel cell therapy's potential to treat epilepsy and other degenerative diseases like Alzheimer’s disease, and the implications for patients and the future of regenerative medicine. We are deeply grateful for CIRM’s ongoing support, which has been vital to our progress. Neurona remains committed to the vision of regenerative cell therapy that CIRM has championed.
We had the pleasure of chatting with Cory R. Nicholas, PhD, the CEO and Co-Founder of Neurona Therapeutics. We discussed the newest milestone for the clinical-stage company and the importance of funding support from CIRM.